Defining Meaningful Outcomes in Neoadjuvant EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss which outcomes are most clinically meaningful when evaluating neoadjuvant targeted therapy in early-stage EGFR-mutated non–small cell lung cancer (NSCLC). Dr. Kim highlights that while radiographic response can provide early insight into treatment activity, pathologic response and the ability to proceed to successful surgical resection are often more impactful in the curative-intent setting. The discussion emphasizes that surgical feasibility and preservation of operability remain critical considerations when incorporating neoadjuvant approaches. Dr. Kim also notes that clinicians must balance tumor response with maintaining appropriate timing for surgery. The panel reflects on how evolving evidence is shaping how these endpoints are interpreted in clinical practice. This segment underscores the importance of selecting meaningful and clinically relevant outcomes to guide treatment decisions in neoadjuvant EGFR-mutated NSCLC.